Brief: Amylyx Pharmaceuticals Q4 EPS USD -0.55
04/03/2025 11:00
Mar 04 (Reuters) - Amylyx Pharmaceuticals Q4 net income USD -37.546 million. Q4 operating income USD -40.654 million Q4 pretax profit USD -38.181 million Q4 operating expenses USD 39.989 million Q4 cash & investments USD 176.5 million
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock